Table 3 Sleep parameters at the beginning and end of the trial
Variable | Group with sleep disorders | Group without sleep disorders | ||||
|---|---|---|---|---|---|---|
Baseline | After Intervention | Baseline | After Intervention | |||
Subjective Sleep Quality | Melatonin | Very good | 0 (0%) | 12 (35.3%) | 11 (32.4%) | 12 (35.3%) |
Fairly good | 7 (20.6%) | 16 (47.1%) | 23 (67.6%) | 22 (64.7%) | ||
Fairly bad | 17 (50%) | 6 (17.6%) | 0 (0%) | 0 (0%) | ||
Very bad | 10 (29.4%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Placebo | Very good | 0 (0%) | 0 (0%) | 6 (17.6%) | 7 (20.6%) | |
Fairly good | 10 (29.4%) | 14 (41.2%) | 28 (82.4%) | 27 (79.4%) | ||
Fairly bad | 14 (41.2%) | 10 (29.4%) | 0 (0%) | 0 (0%) | ||
Very bad | 10 (29.4%) | 10 (29.4%) | 0 (0%) | 0 (0%) | ||
P-Value | 0.635 | < 0.001* | 0.165 | 0.180 | ||
Sleep Latency | Melatonin | < 15 min | 0 (0%) | 12 (35.3%) | 13 (38.2%) | 15 (44.1%) |
16 – 30 min | 8 (23.5%) | 17 (50%) | 17 (50%) | 18 (52.9%) | ||
31 – 60 min | 8 (23.5%) | 3 (8.8%) | 3 (8.8%) | 1 (2.9%) | ||
> 60 min | 18 (52.9%) | 2 (5.9%) | 1 (2.9%) | 0 (0%) | ||
Placebo | < 15 min | 0 (0%) | 0 (0%) | 19 (55.9%) | 20 (58.8%) | |
16 – 30 min | 13 (38.2%) | 13 (38.2%) | 10 (29.4%) | 13 (38.2%) | ||
31 – 60 min | 5 (14.7%) | 5 (14.7%) | 5 (14.7%) | 1 (2.9%) | ||
> 60 min | 16 (47.1%) | 16 (47.1%) | 0 (0%) | 0 (0%) | ||
P-Value | 0.377 | < 0.001* | 0.270 | 0.249 | ||
Sleep Duration | Melatonin | > 7 h | 1 (2.9%) | 15 (44.1%) | 32 (94.1%) | 33 (97.1%) |
6 – 7 h | 12 (35.3%) | 17 (50%) | 1 (2.9%) | 0 (0%) | ||
5 – 6 h | 14 (41.2%) | 2 (5.9%) | 1 (2.9%) | 1 (2.9%) | ||
< 5 h | 7 (20.6) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Placebo | > 7 h | 0 (0%) | 0 (0%) | 33 (97.1%) | 33 (97.1%) | |
6 – 7 h | 16 (47.1%) | 16 (47.1%) | 0 (0%) | 0 (0%) | ||
5 – 6 h | 11 (32.4%) | 11 (32.4%) | 1 (2.9%) | 1 (2.9%) | ||
< 5 h | 7 (20.6) | 7 (20.6) | 0 (0%) | 0 (0%) | ||
P-Value | 0.669 | < 0.001* | 0.569 | 1.000 | ||
Sleep Efficiency | Melatonin | > 85% | 10 (29.4%) | 26 (76.5%) | 33 (97.1%) | 33 (97.1%) |
75 – 84% | 11 (32.4%) | 5 (14.7%) | 1 (2.9%) | 1 (2.9%) | ||
65 – 74% | 10 (29.4%) | 3 (8.8%) | 0 (0%) | 0 (0%) | ||
< 65% | 3 (8.8%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Placebo | > 85% | 9 (26.5%) | 9 (26.5%) | 34 (100%) | 34 (100%) | |
75 – 84% | 10 (29.4%) | 10 (29.4%) | 0 (0%) | 0 (0%) | ||
65 – 74% | 13 (38.2%) | 13 (38.2%) | 0 (0%) | 0 (0%) | ||
< 65% | 2 (5.9%) | 2 (5.9%) | 0 (0%) | 0 (0%) | ||
P-Value | 0.748 | < 0.001* | 0.317 | 0.317 | ||
Sleep Disturbance | Melatonin | Normal | 1 (2.9%) | 5 (14.7%) | 30 (88.2%) | 30 (88.2%) |
Mild | 30 (88.2%) | 28 (82.4%) | 4 (11.8%) | 4 (11.8%) | ||
Moderate | 3 (8.8%) | 1 (2.9%) | 0 (0%) | 0 (0%) | ||
Severe | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Placebo | Normal | 3 (8.8%) | 3 (8.8%) | 32 (94.1%) | 32 (94.1%) | |
Mild | 28 (82.4%) | 28 (82.4%) | 2 (5.9%) | 2 (5.9%) | ||
Moderate | 3 (8.8%) | 3 (8.8%) | 0 (0%) | 0 (0%) | ||
Severe | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
P-Value | 0.537 | 0.251 | 0.396 | 0.396 | ||
Use of Sleep Medication | Melatonin | Not during past month | 34 (0%) | 34 (0%) | 34 (100%) | 34 (100%) |
Less than once a week | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Once or twice a week | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Three or more times a week | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Placebo | Not during past month | 34 (100%) | 34 (100%) | 34 (100%) | 34 (100%) | |
Less than once a week | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Once or twice a week | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Three or more times a week | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
P-Value | 1.000 | 1.000 | 1.000 | 1.000 | ||
Daytime Dysfunction | Melatonin | Normal | 0 (0%) | 6 (17.6%) | 12 (35.3%) | 14 (41.2%) |
Slight Dysfunction | 13 (38.2%) | 21 (61.8%) | 22 (64.7%) | 20 (58.8%) | ||
Moderate Dysfunction | 17 (50%) | 6 (17.6%) | 0 (0%) | 0 (0%) | ||
Severe Dysfunction | 4 (11.8%) | 1 (2.9%) | 0 (0%) | 0 (0%) | ||
Placebo | Normal | 0 (0%) | 0 (0%) | 17 (50%) | 18 (52.9%) | |
Slight Dysfunction | 11 (32.4%) | 13 (38.2%) | 16 (47.1%) | 16 (47.1%) | ||
Moderate Dysfunction | 18 (52.9%) | 16 (47.1%) | 1 (2.9%) | 0 (0%) | ||
Severe Dysfunction | 5 (14.7%) | 5 (14.7%) | 0 (0%) | 0 (0%) | ||
P-Value | 0.583 | < 0.001* | 0.294 | 0.335 | ||